// App-Quantinova.ai

e16538 : Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor.

Researchers

Presenter

  • Daniel J. Coleman

Principal Investigators

  • Kathryn Van Hook

  • Carly J. King

  • Jacob Schwartzman

  • Robert Lisac

  • Joshua Urrutia

  • Archana Sehrawat

  • Josha Woodward

  • Nicholas J. Wang

  • Roman Gulati

  • George V. Thomas

  • Tomasz M. Beer

  • Martin E. Gleave

  • James E. Korkola

  • Lina Gao

  • Laura M. Heiser

  • Joshi J. Alumkal

Medical Centers

  • Knight Cancer Institute, Portland, OR

  • OHSU Knight Cancer Institute, Department of Biomedical Engineering, Portland, OR

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • OHSU Knight Cancer Institute, Department of Biomedical Engineering, Portland, OR

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved